Huali Li

Title: Huali Li: Innovator in Antibody-Drug Conjugates

Introduction

Huali Li is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of biotechnology, particularly in the development of antibody-drug conjugates. With a total of three patents to his name, Huali Li is recognized for his innovative approaches to medical treatments.

Latest Patents

Huali Li's latest patents include groundbreaking work on anti-CD79b antibodies and drug conjugates. The first patent discloses an anti-CD79b antibody or antigen-binding fragment, which comprises specific amino acid sequences that enhance its efficacy. This invention holds promise for targeted therapies in treating various diseases. His second patent focuses on tetramaleimide linkers, which are crucial for the preparation of antibody-drug conjugates. These ADCs, derived from the tetramaleimide linkers, exhibit high homogeneity and stability, making them effective for treating tumors and other diseases.

Career Highlights

Huali Li is currently employed at Newbio Therapeutics, Inc., where he continues to advance his research in biopharmaceuticals. His work has positioned him as a key figure in the development of innovative therapies that leverage the power of antibodies.

Collaborations

Huali Li collaborates with notable colleagues, including Nianhe Han and Deqiang An. Their combined expertise contributes to the success of their projects and the advancement of their research initiatives.

Conclusion

Huali Li's contributions to the field of biotechnology, particularly in antibody-drug conjugates, highlight his role as an influential inventor. His innovative patents and ongoing work at Newbio Therapeutics, Inc. continue to pave the way for advancements in medical treatments.